Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices
PHILADELPHIA, Jan. 15 /PRNewswire/ -- Eli Lilly and Company announced today it has agreed to plead guilty to criminal conduct and to pay more than 1.4 billion in criminal and civil fines, penalties and damages arising from allegations made in multiple whistleblower lawsuits that the pharmaceutical...
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
INDIANAPOLIS, Jan. 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company
(NYSE: LLY ) today announced that it has reached resolution with the United
States Attorney for the Eastern District of Pennsylvania (EDPA) and the Office
of Consumer Litigation of the Department of Justice regarding the
State of Alaska and Eli Lilly and Company Reach Agreement to Settle Zyprexa Lawsuit
INDIANAPOLIS, Ind. and ANCHORAGE, Alaska, March 26 /PRNewswire/ -- Eli
Lilly and Company and the State of Alaska have agreed on the following
Alaska Attorney General Talis J. Colberg and Eli Lilly and Company
(NYSE: LLY ) today announced a settlement of the lawsuit filed by...
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
INDIANAPOLIS, Oct. 5 /PRNewswire-FirstCall/ -- Eli Lilly and Company
announced today that as a part of on-going discussions with the U.S. Food
and Drug Administration (FDA), the company has updated the Zyprexa(R)
(olanzapine) and Symbyax(R) (olanzapine and fluoxetine HCl) U.S. product
Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa
$515 Million Criminal Fine is Largest Individual Corporate Criminal Fine in History;
Civil Settlement Up To $800 Million
WASHINGTON, Jan. 15 /PRNewswire-USNewswire/ -- American pharmaceutical giant Eli Lilly and Company today agreed to plead guilty and pay $1.415 billion for promoting it...
Abilify Has Made Strong Gains in Patient Share Across All Lines of Therapy Since Last Year's Analysis of Prescribing Trends in Schizophrenia
...grew substantially compared with our 2008 analysis whereas both Eli Lilly's zyprexa
and AstraZeneca's Seroquel lost first-line patient share," stated Nicole We...arly lines of therapy, surveyed psychiatrists indicate that risperidone and zyprexa
will lose the most share. These data indicate that marketers of current and...
Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance
... $1.06 $.88 20%
Charge related to zyprexa
litigation .06 -
Restruc...99.7 million of Erbitux revenue.
In the second quarter of 2009, zyprexa
sales totaled $1.203 billion, a decrease of 3 perc...
FDA Panel OKs Newer Antipsychotics for Children
... Seroquel, zyprexa
and Geodon have been linked to certain health risks, experts note,,
WEDNESDAY, June 10 (HealthDay News) -- A U.S. Food and Drug Administra...
FDA Panel Mulls Newer Antipsychotics for Kids
... Seroquel, zyprexa
have been linked to certain health risks, experts note,,
WEDNES...ity, and finally, physicians may continue prescribing Geodon, Seroquel, and zyprexa
off-label to children, as we continue to grow this knowledge base."
Olanzapine Long-Acting Injection (LAI) Efficacy and Safety Data Presented at American Psychiatric Association Annual Meeting
Safety information for Oral zyprexa
is indicated in adults in the United States for th...maintenance treatment of bipolar disorder.
is not approved for the treatment of patients with...
Zyprexa in Medical Technology
Zyprexa in Biological News
FDA Warns About Antipsychotic Drugs and Elderly
...ith their use compared to patients receiving a placebo (sugar pill).
Today's advisory applies to such antipsychotic drugs as Abilify (aripiprazole), zyprexa
(olanzapine), Seroquel (quetiapine), Risperdal (risperidone), Clozaril (clozapine) and Geodon (ziprasidone). Symbyax, which is approved for treatment ...
Zyprexa in Biological Technology
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
...all cell lung cancer
and advanced, metastatic head and neck cancer.
continues to provide a stable revenue base, despite generic
competition in ...itutional market volume is
growing for the first time in five years. Future zyprexa
sales should benefit
from a long-acting formulation, olanzapine LAI, which ...
Lilly to Take Charge to Earnings Related to Pending Federal and State Investigations of Past Practices
...ed to past marketing and
promotional practices for zyprexa
in the United States. Lilly has now
incorporated a...eneral counsel. "The government's
investigation of zyprexa
has been ongoing for five years and we now have a
...) related to the sales, marketing and
promotion of zyprexa
for $62 million. In March, Lilly entered into a $1...
Lilly Reports Solid Second-Quarter Results
... response to the FDA's
not-approvable decision for zyprexa
-- The FDA approved Strat... ----
In the second quarter of 2008, zyprexa
sales totaled $1.240 billion, a
2 percent increase...both net selling prices and volume was negligible. zyprexa
international markets increased 4 percent...
Lilly Reports Solid First-Quarter Results
...he U.S. Food and Drug Administration (FDA) for zyprexa
long-acting injection for the treatment and ma...ettle a lawsuit filed by the state over use of zyprexa
by the state's Medicaid program. The agreement...s, including a $15.0 million settlement
related to zyprexa
litigation with the state of Alaska. Research and
Manhattan Research Ranks the Top Pharmaceutical Branded Websites by Rx Request Rates
Seasonale, Seroquel, Singulair, Strattera, Tamiflu, Topamax, Toprol XL,
Tricor, Valtrex, Vytorin, Yasmin, Yaz, Zocor, Zoloft, Zomig, zyprexa
Please visit http://www.manhattanresearch.com/ePC.htm to download the ePharma
Consumer(R) product brochure, request subscription infor...
Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
...f therapy, largely owing to its first-in-class status among the
antipsychotics to treat both mania and depression. Janssen's Risperdal and
Eli Lilly's zyprexa
suffered the greatest losses, losing a combined 11.9%
patient share first line over the same time period. About Treatment Algorithm Insight Series D...
Big Pharma's continued hunger and search for new products
...spiratory Disorders/Asthma $5.6 +19% 5. Zocor Merck) Cholesterol Reduction $5.3 6. Norvasc (Pfizer) Hypertension/Angina $5.0 +3% 7. zyprexa
(Eli Lily) Antidepressant $4.7 8. Risperdal (Janssen- Ortho/J&J) Anti-psychotic Agent $4.0 +13% 9. Prevacid (Abbott/Takeda) Gastrointes...